rospective Study to Assess Fluid Accumulation and Tenosynovial Changes in AI users

[Hopeful]

Ann Oncol. 2012 Oct 4;[Epub Ahead of Print], A Lintermans, A Laenen, B Van Calster, et al

TAKE-HOME MESSAGE

This valuable study used MRI to document possible reasons for joint effects of aromatase inhibitors in patients with breast cancer persisting at 2 years.

Abstract

Background:Aromatase inhibitors (AIs) frequently lead to the AI-induced musculoskeletal syndrome (AIMSS). Looking into its pathophysiology, 6 months of AI therapy thickens the tendon sheath with intra-articular fluid (IAF) retention and loss of grip strength. We here report 24-month follow-up data.

Patients and Methods: A prospective cohort study of 33 postmenopausal breast cancer patients received adjuvant endocrine therapy; 27 received an AI and 6 received tamoxifen. At baseline, 6 and 24 months patients had a rheumatologic examination, including a grip strength test, and magnetic resonance imaging of both hands and wrists. The primary end point was tenosynovial changes; secondary end points were changes in morning stiffness, grip strength and IAF.

Results: Twenty-three AI and 5 tamoxifen patients completed all investigations. Between month 6 and 24, IAF further increased in AI users (P = 0.04) but not in tamoxifen users, and grip strength further decreased in both groups. The worsened tenosynovial changes were strongly correlated with a decrease in grip strength. At 24 months, morning stiffness continued to be present in over a third of AI users.

Conclusion: AIMSS represents a substantial problem in breast cancer patients. It is associated with tenosynovial changes, IAF retention, joint stiffness and loss of grip strength that do not improve with prolonged use.

Hopeful

[Joanne S]

Interesting. Thanks for sharing!

[karen z]

Thanks for posting. The results are important to know about.